Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10945613 | 0.83 | SIGMAR1 (0.59) | TRPV1SIGMAR1KDM4EMEN1KMT2A | |
| SCHEMBL3440742 | 0.82 | MCL1 (0.68) | MCL1TRPV1PTPN1SIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL11015680 | 0.77 | MCL1 (0.60) | MCL1TRPV1PTPN1SIGMAR1KDM4E | |
| SCHEMBL14916225 | 0.77 | ALDH1A1 (0.40) | MEN1MAPTKMT2A | |
| SCHEMBL29349880 | 0.76 | MCL1 (1.00) | MCL1TRPV1PTPN1SIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL6432796 | 0.75 | MCL1 (0.57) | MCL1TRPV1PTPN1SIGMAR1KDM4E | |
| Hydrochloric Acid SCHEMBL7638732 | 0.75 | MCL1 (0.57) | MCL1TRPV1PTPN1SIGMAR1KDM4E | |
| SCHEMBL2709841 | 0.74 | MEN1 (0.38) | TRPV1MEN1MAPTKMT2A | |
| SCHEMBL25969106 | 0.74 | MCL1 (0.65) | MCL1TRPV1PTPN1KDM4EMEN1 | |
| SCHEMBL206372 | 0.72 | MCL1 (0.58) | MCL1TRPV1PTPN1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | BAYER HEALTHCARE AG (DE) | 2004-12-23 | — | — | US | disclosed |
| EP-1414788-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014064-A1 | NAPHTHYLUREA AND NAPHTHYLACETAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259875-A1 | Amine derivatives | AVPR1A, GRIN1, OPRL1 | MCL1 2609/4885TRPV1 14/4885PTPN1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.